This is a news story, published by Yahoo Finance, that relates primarily to Pfizer news.
For more Pfizer news, you can click here:
more Pfizer newsFor more stocks trading & speculation news, you can click here:
more stocks trading & speculation newsFor more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like stocks trading & speculation news, you might also like this article about
Pfizer Stock. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest big pharma business news, best stocks news, stocks trading & speculation news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
PfizerThe Motley Fool
•78% Informative
Pfizer 's total return of its shares is down by 19% over the last three years .
The company's trailing 12-month revenue rose by only 6% , reaching $58.5 billion , and net income over that period fell by 83% .
Pfizer currently has 31 programs in clinical trials, and 34 programs in phase 2 trials.
In its recently bolstered oncology pipeline, management thinks that within the next six years it'll have a minimum of eight medicines that could be blockbuster drugs.
The 10 stocks that made the cut could produce monster returns in the coming years . Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month . The Stock Advisor service has more than tripled the return of S&P 500 since 2002
.
Stock Advisor returns as of April 8, 2024 Is Pfizer Stock a Buy? was originally published by The Motley Fool .
VR Score
77
Informative language
74
Neutral language
29
Article tone
informal
Language
English
Language complexity
41
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
7
Source diversity
2
Affiliate links
no affiliate links